Elevated Maresin‐1 Levels in Pericardial Fluid of Patients Undergoing Coronary Artery Bypass Grafting
Catheterization and Cardiovascular Interventions · 2026-06 · 107 (7) · 2304-2311
DOI: 10.1002/ccd.70612 ↗At a glance
Journal article in Catheterization and Cardiovascular Interventions, published online on 2026-04-06. Written by Reşat Dikme and 1 co-authors. Institution: Department of Perfusion Technology/Dialysis, Vocational School of Health Services, Harran University, Şanlıurfa, Turkey. Major MEDLINE topics: Coronary Artery Bypass, Pericardial Fluid, Coronary Artery Disease, Docosahexaenoic Acids. 20 references.
Abstract (original language)
Background
Chronic inflammation plays a critical role in the pathophysiology of cardiovascular diseases. Specialized pro‐resolving mediators derived from omega‐3 fatty acids, such as Maresin‐1 (MaR1), have been shown to promote inflammation resolution and exert cardioprotective effects. However, the clinical significance of MaR1 in coronary artery bypass grafting (CABG) patients remains unclear.
Aims
This study aimed to investigate MaR1 levels in plasma and pericardial fluid of patients undergoing elective coronary artery bypass grafting and to evaluate its potential as a biomarker of localized cardiac inflammatory resolution.
Methods
This cross‐sectional analytic study included 50 patients undergoing elective CABG and 50 age‐ and sex‐matched healthy controls. Plasma and pericardial fluid were collected from patients,and plasma from controls. MaR1 levels were quantified by ELISA. Group comparisons were performed using Kruskal–Wallis and Mann–Whitney U tests. Diagnostic performance was evaluated by receiver operating characteristic (ROC) analysis, and independent predictive value was assessed using multivariablelogistic regression.
Results
MaR1 levels were significantly higher in pericardial fluid (97.03 pg/mL) compared with patient plasma (61.02 pg/mL) and controls (42.45 pg/mL) ( p < 0.001). ROC analysis demonstrated high discriminative performance (AUC = 0.975; sensitivity 93%, specificity 100%). Logistic regression confirmed MaR1 as an independent predictor of patient status after adjustment for age and sex (OR = 1.88, p < 0.001).
Conclusion
The marked elevation of MaR1 in pericardial fluid reflects a localized resolution response in the cardiac microenvironment, underscoring its potential as a distinctive biomarker in cardiovascular disease. These findings suggest that MaR1 may serve as a novel biomarker reflecting localized cardiac inflammatory resolution in patients with coronary artery disease.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Perfusion Technology/Dialysis, Vocational School of Health Services, Harran University, Şanlıurfa, Turkey.
- Department of Perfusion, Faculty of Health Sciences, Harran University, Şanlıurfa, Turkey.
ORCID profiles: Reşat Dikme, Mahmut Padak
Cite
APA
Dikme, R., & Padak, M. (2026). Elevated Maresin‐1 Levels in Pericardial Fluid of Patients Undergoing Coronary Artery Bypass Grafting. Catheterization and Cardiovascular Interventions, 107(7), 2304-2311. https://doi.org/10.1002/ccd.70612
Vancouver
Dikme R, Padak M. Elevated Maresin‐1 Levels in Pericardial Fluid of Patients Undergoing Coronary Artery Bypass Grafting. Catheterization and Cardiovascular Interventions. 2026;107(7):2304-2311. doi:10.1002/ccd.70612
BibTeX
@article{Dikme2026,
author = {Dikme, Reşat and Padak, Mahmut},
title = {Elevated Maresin‐1 Levels in Pericardial Fluid of Patients Undergoing Coronary Artery Bypass Grafting},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {107},
number = {7},
pages = {2304--2311},
doi = {10.1002/ccd.70612}
}
EUVIMED